CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade Better Therapeutics, Inc. - BTTX CFD

0.6830
2.2%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0562
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025457%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003235%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.6683
Open* 0.6671
1-Year Change* -67.3%
Day's Range* 0.6486 - 0.7027
52 wk Range 0.59-2.80
Average Volume (10 days) 135.87K
Average Volume (3 months) 2.90M
Market Cap 21.89M
P/E Ratio -100.00K
Shares Outstanding 31.73M
Revenue N/A
EPS -1.67
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Aug 9, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
May 26, 2023 0.6830 0.0159 2.38% 0.6671 0.7263 0.6480
May 25, 2023 0.6683 -0.0257 -3.70% 0.6940 0.7422 0.6483
May 24, 2023 0.7168 -0.0290 -3.89% 0.7458 0.7459 0.6924
May 23, 2023 0.7507 0.0054 0.72% 0.7453 0.7651 0.7453
May 22, 2023 0.7555 0.0201 2.73% 0.7354 0.7942 0.7354
May 19, 2023 0.7564 0.0013 0.17% 0.7551 0.7747 0.7540
May 18, 2023 0.7554 -0.0015 -0.20% 0.7569 0.7845 0.7356
May 17, 2023 0.7582 0.0126 1.69% 0.7456 0.7797 0.7456
May 16, 2023 0.7620 -0.0388 -4.85% 0.8008 0.8037 0.7260
May 15, 2023 0.7457 -0.0580 -7.22% 0.8037 0.8136 0.7359
May 12, 2023 0.7470 0.0310 4.33% 0.7160 0.7749 0.7159
May 11, 2023 0.7555 -0.0823 -9.82% 0.8378 0.8571 0.7257
May 10, 2023 0.8349 0.0215 2.64% 0.8134 0.8716 0.7544
May 9, 2023 0.8039 0.0391 5.11% 0.7648 0.8137 0.7262
May 8, 2023 0.7746 -0.1165 -13.07% 0.8911 0.8911 0.6907
May 5, 2023 0.9005 0.0042 0.47% 0.8963 0.9298 0.8905
May 4, 2023 0.9297 -0.1353 -12.70% 1.0650 1.0653 0.8708
May 3, 2023 1.0750 0.0017 0.16% 1.0733 1.1041 1.0635
May 2, 2023 1.0944 0.0095 0.88% 1.0849 1.1233 1.0652
May 1, 2023 1.0943 -0.0281 -2.50% 1.1224 1.1332 1.0741

Better Therapeutics, Inc. Events

Time (UTC) Country Event
Wednesday, August 9, 2023

Time (UTC)

20:00

Country

US

Event

Q2 2023 Better Therapeutics Inc Earnings Release
Q2 2023 Better Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Monday, November 13, 2023

Time (UTC)

21:00

Country

US

Event

Q3 2023 Better Therapeutics Inc Earnings Release
Q3 2023 Better Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020
Total revenue 0 0 0
Total Operating Expense 38.262 40.303 0.00169
Other Operating Expenses, Total 0.00169
Operating Income -38.262 -40.303 -0.00169
Net Income Before Taxes -39.753 -40.488 -0.00169
Net Income After Taxes -39.76 -40.335 -0.00169
Net Income Before Extra. Items -39.76 -40.335 -0.00169
Net Income -39.76 -40.335 -0.00169
Income Available to Common Excl. Extra. Items -39.76 -40.335 -0.00169
Income Available to Common Incl. Extra. Items -39.76 -40.335 -0.00169
Diluted Net Income -39.76 -40.335 -0.00169
Diluted Weighted Average Shares 23.5578 23.6027 7.5575
Diluted EPS Excluding Extraordinary Items -1.68776 -1.70891 -0.00022
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -1.68776 -1.4406 -0.00022
Selling/General/Admin. Expenses, Total 21.822 11.124
Research & Development 16.44 19.436
Unusual Expense (Income) 0 9.743
Interest Income (Expense), Net Non-Operating -1.491 -0.185
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 0 0 0 0 0
Total Operating Expense 8.925 8.322 10.996 9.599 9.345
Other Operating Expenses, Total
Operating Income -8.925 -8.322 -10.996 -9.599 -9.345
Interest Income (Expense), Net Non-Operating -0.431 -0.439 -0.406 -0.329 -0.317
Net Income Before Taxes -9.356 -8.761 -11.402 -9.928 -9.662
Net Income After Taxes -9.357 -8.765 -11.405 -9.928 -9.662
Net Income Before Extra. Items -9.357 -8.765 -11.405 -9.928 -9.662
Net Income -9.357 -8.765 -11.405 -9.928 -9.662
Income Available to Common Excl. Extra. Items -9.357 -8.765 -11.405 -9.928 -9.662
Income Available to Common Incl. Extra. Items -9.357 -8.765 -11.405 -9.928 -9.662
Diluted Net Income -9.357 -8.765 -11.405 -9.928 -9.662
Diluted Weighted Average Shares 23.8266 23.6315 23.6931 23.593 23.4132
Diluted EPS Excluding Extraordinary Items -0.39271 -0.3709 -0.48136 -0.4208 -0.41267
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.39271 -0.3709 -0.48136 -0.4208 -0.41267
Selling/General/Admin. Expenses, Total 5.536 5.273 5.519 5.358 5.672
Research & Development 3.389 3.049 5.477 4.241 3.673
Unusual Expense (Income) 0 0 0 0
  • Annual
  • Quarterly
2022 2021 2020
Total Current Assets 18.446 45.251 0.08666
Cash and Short Term Investments 15.74 40.566 0.02476
Cash 0.02476
Other Current Assets, Total 0.21 0.276 0.06189
Total Assets 22.943 50.958 0.08666
Total Current Liabilities 13.494 4.733 0.06334
Accrued Expenses 5.927 3.21 0.00145
Notes Payable/Short Term Debt 0 0 0.06189
Total Liabilities 23.842 14.238 0.06334
Total Long Term Debt 10.348 9.505 0
Total Equity -0.899 36.72 0.02331
Common Stock 0.002 0.002 0.00014
Additional Paid-In Capital 110.602 108.461 0.02486
Retained Earnings (Accumulated Deficit) -111.503 -71.743 -0.00169
Total Liabilities & Shareholders’ Equity 22.943 50.958 0.08666
Total Common Shares Outstanding 23.851 23.6027 7.5575
Cash & Equivalents 15.74 40.566
Prepaid Expenses 2.496 4.409
Property/Plant/Equipment, Total - Net 0.121 0.082
Intangibles, Net 3.888 5.077
Other Long Term Assets, Total 0.488 0.548
Accounts Payable 3.035 1.523
Long Term Debt 10.348 9.505
Property/Plant/Equipment, Total - Gross 0.178
Accumulated Depreciation, Total -0.057
Current Port. of LT Debt/Capital Leases 4.532
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 8.442 18.446 23.49 32.137 35.179
Cash and Short Term Investments 6.068 15.74 22.305 29.685 31.673
Cash
Prepaid Expenses 1.968 2.496 1.123 2.38 3.242
Total Assets 12.808 22.943 28.221 37.103 40.291
Long Term Investments
Other Long Term Assets, Total 0.483 0.488 0.488 0.487 0.488
Total Current Liabilities 13.64 13.494 9.312 6.141 3.567
Accrued Expenses 5.588 5.927 4.928 3.27 2.528
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 22.641 23.842 20.969 19.049 12.866
Total Long Term Debt 9.001 10.348 11.657 12.908 9.299
Other Liabilities, Total
Total Equity -9.833 -0.899 7.252 18.054 27.425
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 111.025 110.602 109.988 109.385 108.828
Retained Earnings (Accumulated Deficit) -120.86 -111.503 -102.738 -91.333 -81.405
Total Liabilities & Shareholders’ Equity 12.808 22.943 28.221 37.103 40.291
Total Common Shares Outstanding 23.8523 23.851 23.7441 23.733 23.6086
Payable/Accrued
Cash & Equivalents 6.068 15.74 22.305 29.685 31.673
Other Current Assets, Total 0.406 0.21 0.062 0.072 0.264
Property/Plant/Equipment, Total - Net 0.131 0.121 0.122 0.115 0.098
Intangibles, Net 3.752 3.888 4.121 4.364 4.526
Accounts Payable 2.513 3.035 1.255 1.088 0.735
Long Term Debt 9.001 10.348 11.657 12.908 9.299
Current Port. of LT Debt/Capital Leases 5.539 4.532 3.129 1.783 0.304
  • Annual
  • Quarterly
2022 2021 2020
Net income/Starting Line -39.76 -40.335 -0.00169
Cash From Operating Activities -28.93 -30.818 -0.00024
Changes in Working Capital 6.268 -2.339 0.00145
Cash From Financing Activities 5.284 72.332 0.025
Financing Cash Flow Items 0 62.331 -0.06189
Issuance (Retirement) of Stock, Net 0.284 0.001 0.025
Issuance (Retirement) of Debt, Net 5 10 0.06189
Net Change in Cash -24.826 40.443 0.02476
Cash From Operating Activities 2.729 1.619
Deferred Taxes 0 -0.152
Non-Cash Items 1.833 10.389
Cash Interest Paid 1.325 0.085
Cash From Investing Activities -1.18 -1.071
Capital Expenditures -1.18 -1.071
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -9.357 -39.76 -30.995 -19.59 -9.662
Cash From Operating Activities -8.716 -28.93 -22.593 -15.57 -8.855
Non-Cash Items 0.41 1.833 1.384 0.787 0.375
Changes in Working Capital -0.524 6.268 5.01 1.919 -0.231
Cash From Investing Activities -0.521 -1.18 -0.82 -0.457 -0.039
Other Investing Cash Flow Items, Total
Cash From Financing Activities -0.435 5.284 5.152 5.146 0.001
Financing Cash Flow Items 0 0 0 0
Issuance (Retirement) of Stock, Net 0 0.284 0.152 0.146 0.001
Issuance (Retirement) of Debt, Net -0.435 5 5 5
Net Change in Cash -9.672 -24.826 -18.261 -10.881 -8.893
Cash From Operating Activities 0.755 2.729 2.008 1.314 0.663
Deferred Taxes 0 0 0 0
Cash Interest Paid 0.495 1.325 0.87 0.462 0.219
Capital Expenditures -0.521 -1.18 -0.82 -0.457 -0.039
Cash Taxes Paid 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Perry (David P) Individual Investor 53.1606 16868581 6404566 2023-04-12 LOW
Georgianna Maule-Ffinch 2015 Trust Individual Investor 11.4598 3636364 3636364 2023-04-10
Appelbaum (Kevin J) Individual Investor 7.5847 2406719 -6250 2023-04-10 LOW
Mountain Crest Capital LLC Corporation 4.375 1388250 0 2023-04-10 LOW
Farallon Capital Management, L.L.C. Hedge Fund 2.203 699042 -114514 2023-03-31 MED
Armanino (Andrew J) Individual Investor 1.4739 467692 303030 2023-04-10 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.3818 438479 3700 2023-03-31 LOW
Parker (Geoffrey M) Individual Investor 1.2491 396363 303030 2023-04-10 LOW
Maule-Ffinch (Georgianna) Individual Investor 0.9238 293150 0 2023-04-10 LOW
Karbe (Frank L) Individual Investor 0.9216 292424 242424 2023-04-10 MED
Berman Mark A Individual Investor 0.7309 231939 0 2023-04-10 LOW
Carmona (Richard H. M.D.) Individual Investor 0.4841 153619 0 2023-04-10 LOW
Wynholds (Kristin) Individual Investor 0.3114 98819 0 2023-04-10 LOW
Heinen (Mark) Individual Investor 0.2773 88004 1 2023-04-10 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.2523 80054 798 2023-03-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.18 57109 0 2023-03-31 LOW
Susquehanna International Group, LLP Investment Advisor 0.1497 47516 -6473 2023-03-31 MED
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.1424 45200 0 2023-03-31 LOW
Zamirowski (Justin) Individual Investor 0.1163 36913 36913 2022-05-27
Millennium Management LLC Hedge Fund 0.0837 26556 14932 2023-03-31 HIGH

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

530K+

Traders

87K+

Active clients monthly

$46M+

Monthly investing volume

$31M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Better Therapeutics, Inc. Company profile

About Better Therapeutics Inc

Better Therapeutics, Inc, formerly Mountain Crest Acquisition Corp II, is engaged in offering prescription digital therapeutics platform for treating cardiometabolic diseases. The Company creates treatments to reverse the progression of disease, improve quality of life, and inform clinical decisions. It builds prescription digital therapeutics that deliver a new kind of behavioral therapy and creating feedback mechanisms using remotely-monitored and patient-generated data. Its clinical development pipeline includes BT-001, BT-002, BT-003, BT-004 and BT-005. It is evaluating BT-001 in a pivotal study as a prescribed treatment used under physician supervision for people with uncontrolled type 2 diabetes. The Company develops Nutritional Cognitive Behavioral Therapy (Nutritional CBT), which is a novel form of behavioral therapy under development for the treatment of patients with type 2 diabetes and other cardiometabolic diseases.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Better Therapeutics Inc revenues was not reported. Net loss totaled to $550K.

Industry: Biotechnology & Medical Research (NEC)

548 Market St. #49404
SAN FRANCISCO
CALIFORNIA 94101
US

Income Statement

  • Annual
  • Quarterly

People also watch

Oil - Crude

72.94 Price
+1.570% 1D Chg, %
Long position overnight fee -0.0154%
Short position overnight fee -0.0065%
Overnight fee time 21:00 (UTC)
Spread 0.04

Gold

1,946.90 Price
+0.290% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 21:00 (UTC)
Spread 0.60

XRP/USD

0.47 Price
+1.040% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00319

BTC/USD

27,231.90 Price
+1.710% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

Still looking for a broker you can trust?

Join the 530.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading